Skip to main content
. 2020 Dec 24;6(3):853–856. doi: 10.1016/j.ekir.2020.12.006

Table 2.

Key teaching points

  • Temporal relationship between the onset of worsening kidney function and administration of actinium-225 (225Ac)–prostate-specific membrane antigen (PSMA)617 in our patients is very suggestive of a drug association. Moreover, biopsy findings and their similarity to animal models of this type of injury is strongly suggestive of therapy-related toxicity.

  • Our cases emphasize the need for careful assessment and long-term monitoring of kidney function in patients receiving targeted radionuclide therapy with 225Ac-PSMA617, especially if preexisting kidney impairment is present.

  • As with many newer promising cancer therapies, unforeseen kidney risks may be present and practitioners in both nephrology and oncology must be aware of these potential adverse effects.